Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$25.95 -2.5%	$28.41	$23.91 ▼ $46.99	$1.97B	1.6	593,253 shs	483,262 shs
LNTH Lantheus	$99.29 -1.5%	$91.87	$56.44 ▼ $126.89	$6.80B	0.38	947,736 shs	724,120 shs
ROIV Roivant Sciences	$10.42 -1.7%	$10.83	$9.76 ▼ $13.06	$7.44B	1.26	4.53 million shs	4.44 million shs
RVMD Revolution Medicines	$39.03 -0.4%	$41.18	$29.55 ▼ $62.40	$7.26B	1.46	1.36 million shs	845,376 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	-2.52%	-3.85%	-5.70%	-9.77%	-34.78%
LNTH Lantheus	-1.55%	-0.94%	+21.20%	+6.74%	+66.37%
ROIV Roivant Sciences	-1.70%	-1.70%	-0.67%	-11.99%	-1.88%
RVMD Revolution Medicines	-0.43%	-0.48%	-5.84%	-13.29%	+17.38%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CGON CG Oncology	1.7358 of 5 stars	3.6	2.0	0.0	2.2	0.8	0.0
LNTH Lantheus	4.636 of 5 stars	3.5	3.0	4.2	3.4	2.5	1.9
ROIV Roivant Sciences	2.0007 of 5 stars	3.5	0.0	0.0	2.9	3.3	0.0
RVMD Revolution Medicines	4.1809 of 5 stars	4.5	0.0	4.7	2.7	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGON CG Oncology	3.10	Buy	$63.88	146.15% Upside
LNTH Lantheus	3.00	Buy	$132.86	33.81% Upside
ROIV Roivant Sciences	3.00	Buy	$18.08	73.54% Upside
RVMD Revolution Medicines	3.08	Buy	$66.31	69.89% Upside

Current Analyst Ratings Breakdown

Latest CGON, ROIV, LNTH, and RVMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/7/2025	CGON CG Oncology	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$55.00 ➝ $55.00
3/4/2025	ROIV Roivant Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/3/2025	RVMD Revolution Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$72.00 ➝ $73.00
2/27/2025	LNTH Lantheus	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$120.00 ➝ $127.00
2/27/2025	RVMD Revolution Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$67.00
2/27/2025	RVMD Revolution Medicines	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $78.00
2/27/2025	RVMD Revolution Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$60.00 ➝ $59.00
2/11/2025	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
1/30/2025	ROIV Roivant Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
1/14/2025	LNTH Lantheus	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$112.00 ➝ $112.00
1/10/2025	CGON CG Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00

(Data available from 3/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGON CG Oncology	$684K	2,884.78	N/A	N/A	($1.94) per share	-13.38
LNTH Lantheus	$1.53B	4.43	$8.29 per share	11.98	$11.91 per share	8.34
ROIV Roivant Sciences	$122.59M	60.65	N/A	N/A	$7.76 per share	1.34
RVMD Revolution Medicines	$742K	9,779.22	N/A	N/A	$11.09 per share	3.52

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGON CG Oncology	-$48.61M	N/A	0.00	N/A	N/A	-10,642.98%	-18.97%	-15.36%	3/25/2025 (Estimated)
LNTH Lantheus	$326.66M	$4.37	16.52	15.74	N/A	28.57%	44.29%	23.52%	5/1/2025 (Estimated)
ROIV Roivant Sciences	$4.35B	-$0.15	N/A	N/A	N/A	-119.54%	-14.05%	-12.81%	5/29/2025 (Estimated)
RVMD Revolution Medicines	-$436.37M	-$3.57	N/A	N/A	N/A	N/A	-33.67%	-30.08%	5/14/2025 (Estimated)

Latest CGON, ROIV, LNTH, and RVMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/25/2025	N/A	CGON CG Oncology	-$0.37	N/A	N/A	N/A	$0.11 million	N/A
2/27/2025	Q4 2024	LNTH Lantheus	$1.57	$1.34	-$0.23	-$0.17	$376.61 million	$391.11 million
2/26/2025	Q4 2024	RVMD Revolution Medicines	-$1.01	-$1.12	-$0.11	-$1.12	$0.35 million	N/A
2/10/2025	Q3 2025	ROIV Roivant Sciences	-$0.24	-$0.20	+$0.04	$0.23	$4.75 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGON CG Oncology	N/A	35.32	35.32
LNTH Lantheus	N/A	1.65	1.56
ROIV Roivant Sciences	N/A	37.91	37.91
RVMD Revolution Medicines	N/A	14.24	14.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGON CG Oncology	26.56%
LNTH Lantheus	99.06%
ROIV Roivant Sciences	64.76%
RVMD Revolution Medicines	94.34%

Insider Ownership

Company	Insider Ownership
CGON CG Oncology	N/A
LNTH Lantheus	1.50%
ROIV Roivant Sciences	7.90%
RVMD Revolution Medicines	8.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGON CG Oncology	61	76.04 million	N/A	Optionable
LNTH Lantheus	700	68.48 million	68.48 million	Optionable
ROIV Roivant Sciences	860	713.55 million	657.18 million	Optionable
RVMD Revolution Medicines	250	185.91 million	154.76 million	Optionable

CGON, ROIV, LNTH, and RVMD Headlines

Recent News About These Companies

Revolution Medicines’ SWOT analysis: RAS inhibitor stock shows promise amid clinical trials

March 14 at 8:28 AM | investing.com

Victory Capital Management Inc. Trims Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)

March 12 at 3:34 AM | marketbeat.com

Charles Schwab Investment Management Inc. Buys 167,997 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)

March 11 at 3:36 AM | marketbeat.com

Bank of New York Mellon Corp Has $24.89 Million Stock Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)

March 10, 2025 | marketbeat.com

Proficio Capital Partners LLC Purchases New Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)

March 9, 2025 | marketbeat.com

Revolution Medicines, Inc. (NASDAQ:RVMD) is Alphabet Inc.'s 4th Largest Position

March 8, 2025 | marketbeat.com

HC Wainwright Analysts Lower Earnings Estimates for RVMD

March 8, 2025 | americanbankingnews.com

HC Wainwright Issues Pessimistic Forecast for RVMD Earnings

March 7, 2025 | marketbeat.com

E Fund Management Co. Ltd. Raises Stake in Revolution Medicines, Inc. (NASDAQ:RVMD)

March 7, 2025 | marketbeat.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Shares Bought by Candriam S.C.A.

March 7, 2025 | marketbeat.com

Revolution Medicines (NASDAQ:RVMD) versus Protara Therapeutics (NASDAQ:TARA) Financial Review

March 5, 2025 | americanbankingnews.com

HC Wainwright Forecasts Strong Price Appreciation for Revolution Medicines (NASDAQ:RVMD) Stock

March 5, 2025 | americanbankingnews.com

Equities Analysts Issue Forecasts for RVMD Q3 Earnings

March 4, 2025 | americanbankingnews.com

Revolution Medicines, Inc. (RVMD): Among the Cash-Rich Mid Cap Stocks to Buy Now

March 3, 2025 | insidermonkey.com

Revolution Medicines (NASDAQ:RVMD) Price Target Raised to $73.00

March 3, 2025 | marketbeat.com

Analysts Are Bullish on Top Healthcare Stocks: uniQure (QURE), Revolution Medicines (RVMD)

March 3, 2025 | markets.businessinsider.com

Q3 Earnings Estimate for RVMD Issued By Leerink Partnrs

March 3, 2025 | marketbeat.com

Wedbush Lifts Earnings Estimates for Revolution Medicines

March 3, 2025 | marketbeat.com

New York State Common Retirement Fund Buys 7,244 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)

March 2, 2025 | marketbeat.com

Revolution Medicines, Inc.: Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress

March 1, 2025 | finanznachrichten.de

Revolution Medicines (NASDAQ:RVMD) Given "Outperform" Rating at Wedbush

February 28, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGON, ROIV, LNTH, and RVMD Company Descriptions

CG Oncology NASDAQ:CGON

$25.95 -0.67 (-2.52%)

Closing price 03/13/2025 04:00 PM Eastern

Extended Trading

$26.07 +0.12 (+0.46%)

As of 07:56 AM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Lantheus NASDAQ:LNTH

$99.29 -1.56 (-1.55%)

Closing price 03/13/2025 04:00 PM Eastern

Extended Trading

$100.34 +1.05 (+1.06%)

As of 08:29 AM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Roivant Sciences NASDAQ:ROIV

$10.42 -0.18 (-1.70%)

Closing price 03/13/2025 04:00 PM Eastern

Extended Trading

$10.40 -0.02 (-0.18%)

As of 08:24 AM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Revolution Medicines NASDAQ:RVMD

$39.03 -0.17 (-0.43%)

Closing price 03/13/2025 04:00 PM Eastern

Extended Trading

$40.23 +1.20 (+3.07%)

As of 07:47 AM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time